Physician profile
Mary Ivey
NPI 1427137231
$7,739.19
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,057 · 2020: $1,528 · 2021: $1,901 · 2022: $753 · 2023: $322 · 2024: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.98 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,718.96 | 2020-2021 | |
| Minerva Surgical, INC | $2,473.70 | 2019-2021 | |
| Abbvie INC. | $748.97 | 2019-2024 | |
| Astellas Pharma US INC | $321.83 | 2019-2023 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $174.13 | 2022 | |
| Amgen INC. | $137.85 | 2019-2021 | |
| Conmed Corporation | $123.09 | 2019 | |
| Acclarent, INC | $103.93 | 2022 | |
| Allergan, INC. | $95.97 | 2019-2022 | |
| Gynesonics, INC. | $82.79 | 2021 | |
| Aspira Women'S Health INC | $80.70 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.97 | 2021-2023 | |
| Myovant Sciences INC. | $67.15 | 2022 | |
| Organon LLC | $61.60 | 2022-2023 | Nexplanon |
| Becton, Dickinson and Company | $60.16 | 2023 | Bd Onclarity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $55.68 | 2021-2022 | |
| Channel Medsystems, INC. | $50.35 | 2022-2023 | |
| Coopersurgical, INC. | $49.30 | 2019-2022 | |
| Hologic Sales and Service, LLC | $39.55 | 2019-2023 | Novasure |
| Alexion Pharmaceuticals, INC. | $36.95 | 2019-2020 | |
| Axonics, INC. | $35.47 | 2021-2022 | |
| Therapeuticsmd, INC. | $25.91 | 2021-2022 | |
| Smith+Nephew, INC. | $25.41 | 2022 | |
| Baxter Healthcare | $21.24 | 2021 | |
| Daiichi Sankyo INC. | $21.01 | 2020 | |
| Sumitomo Pharma America, INC. | $19.70 | 2023 | Myfembree |
| Medtronic, INC. | $18.68 | 2024 | Truclear |
| Merck Sharp & Dohme LLC | $18.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ivey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.